Myeloma UK Launches Research Program Focused on Trial Design
In a continuing effort to support and advance early-phase multiple myeloma studies in the United Kingdom, Myeloma UK is launching a patient-focused research…
News
Request for Darzalex as Faster and Easier Under-the-skin Infusion for Multiple Myeloma Before FDA
Janssen has asked the U.S. Food and Drug Administration (FDA) to approve a new subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) as a…
Specific DNA Rearrangement Predicts Treatment Resistance, Poor Outcomes in Multiple Myeloma, Study Suggests
A genomic rearrangement involving the immunoglobulin lambda (IgL) gene is predictive of resistance to immunomodulatory agents and poor outcomes among multiple myeloma patients, a new…
FDA Will Review Isatuximab as Potential Therapy for Hard-to-treat Multiple Myeloma
The U.S. Food and Drug Admnistration (FDA) has agreed to review Sanofi’s biologics license application (BLA) for its investigational antibody, isatuximab, as a potential…
FDA Lifts Hold on Phase 3 Trial Testing Venclexta in Myeloma Patients with Common Genetic Abnormality
The U.S. Food and Drug Administration (FDA) has lifted its hold on the CANOVA Phase 3 clinical trial, which is evaluating the experimental therapeutic…
FDA Approves Xpovio Combo for Heavily Treated RRMM Patients
The U.S. Food and Drug Administration (FDA) has approved — with conditions — Xpovio (selinexor) tablets, in combination with the corticosteroid…
Scientists Find ‘On/off Switch’ of Malignant MM Cancer Cells, May Lead to New Therapies, Study Says
Scientists discovered a set of genes that work as an “on/off switch” for malignant multiple myeloma cancer cells, which may shed light into new…
FDA Approves Darzalex-Revlimid-dexamethasone Combo to Treat Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved Janssen‘s Darzalex (daratumumab), used in combination with Revlimid…
Empliciti Combo Prolongs Survival in Difficult-to-Treat Multiple Myeloma, New Phase 2 Trial Data Show
Adding Empliciti (elotuzumab) to a regimen including Pomalyst (pomalidomide) and low-dose dexamethasone extended survival and the time without disease progression in patients with relapsed…
Selinexor Combo Yields Strong Responses in Difficult-to-treat Multiple Myeloma
Selinexor in combination with dexamethasone and Pomalyst (pomalidomide) leads to strong and durable anti-cancer responses, without significant side effects, in patients with…
